https://www.selleckchem.com/pr....oducts/terfenadine.h
Aim To assess symptoms, healthcare resource utilization and health-related quality of life in advanced renal cell carcinoma (aRCC) clinical practice. Materials methods The USA point-in-time survey of physicians and patients was conducted between February and September 2019. Results Data were available for 227 patients. Mean (standard deviation) number of symptoms was 3.4 (3.2); differences were observed across International Metastatic RCC Database Consortium risk categories (p less then 0.001), with fewer symptoms in favorable
Like
Comment
Share
